Scalable expansion of potent genetically modified human langerhans cells in a closed system for clinical applications

Journal of Immunotherapy

Volumn 30, Issue 6, 2007, Pages 634-643

  Yuan, Jianda ^a,c   Kendle, Ryan ^e   Ireland, Joanna ^e   Heller, Glenn ^d   Sadelain, Michel ^e,f,g   Young, James W ^a,b,c   Rivière, Isabelle ^e,f,g  

^a Laboratory of Cellular Immunobiology   (United States)

^b Bone Marrow Transplant Service   (United States)

^c Division of Hematology/Oncology   (United States)

^d Division of Biostatistics   (United States)

^e Gene Transfer and Somatic Cell Engineering Facility   (United States)

^f Immunology Program   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

APC function; Closed system; Dendritic cells; Expansion; Immunotherapy

Indexed keywords

DENDRITIC CELL VACCINE; GAMMA INTERFERON; RETROVIRUS VECTOR; TUMOR ANTIGEN; VIRUS ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CD34 SELECTION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; DNA MODIFICATION; GOOD MANUFACTURING PRACTICE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INTERFERON PRODUCTION; LANGERHANS CELL; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGENS, CD34; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CRYOPRESERVATION; CYTOKINES; HEMATOPOIETIC STEM CELLS; HUMANS; LANGERHANS CELLS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MONOPHENOL MONOOXYGENASE; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC; VIRAL MATRIX PROTEINS;

EID: 34547777832     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31804efc8b     Document Type: Article

References (34)

1. Ribas A. Genetically modified dendritic cells for cancer immunotherapy. Curr Gene Ther. 2005;5:619-628.
2. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5:296-306.
3. Celluzzi CM, Mayordomo JI, Storkus WJ, et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med. 1996;183:283-287.
4. Davis ID, Jefford M, Parente P, et al. Rational approaches to human cancer immunotherapy. J Leukoc Biol. 2003;73:3-29.
5. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.
6. Caux C, Massacrier C, Vanbervliet B, et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF + TNF alpha. Adv Exp Med Biol. 1997;417:21-25.
7. Ratzinger G, Baggers J, de Cos MA, et al. Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or crosspriming, than do dermal-interstitial or monocyte-derived dendritic cells. J Immunol. 2004;173:2780-2791 [Erratum in J Immunol. 2005;2174:3818].
8. Lodolce JP, Boone DL, Chai S, et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity. 1998;9:669-676.
9. Kennedy MK, Glaccum M, Brown SN, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med. 2000;191:771-780.
10. Lu J, Giuntoli RL II, Omiya R, et al. Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes. Clin Cancer Res. 2002;8:3877-3884.
11. Becker TC, Wherry EJ, Boone D, et al. Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J Exp Med. 2002;195:1541-1548.
12. Yuan J, Latouche J-B, Reagan JL, et al. Langerhans cells derived from genetically modified human CD34+ hemopoietic progenitors are more potent than peptide-pulsed Langerhans cells for inducing antigen-specific CD8+ cytolytic T lymphocyte responses. J Immunol. 2005;174:758-766.
13. zum Buschenfelde CM, Metzger J, Hermann C, et al. The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells. J Immunol. 2001;167:1712-1719.
14. Guidance for Industry INDs - Approaches to Complying with CGMP During Phase 1", Draft January 2006.
15. Gatti E, Velleca MA, Biedermann BC, et al. Large-scale culture and selective maturation of human Langerhans cells from granulocyte colony-stimulating factor-mobilized CD34+ progenitors. J Immunol. 2000;164:3600-3607.
16. Guyre CA, Fisher JL, Waugh MG, et al. Advantages of hydrophobic culture bags over flasks for the generation of monocyte-derived dendritic cells for clinical applications. J Immunol Methods. 2002;262:85-94.
17. Tuyaerts S, Noppe SM, Corthals J, et al. Generation of large numbers of dendritic cells in a closed system using Cell Factories. J Immunol Methods. 2002;264:135-151.
18. Seager Danciger J, Lutz M, Hama S, et al. Method for large scale isolation, culture and cryopreservation of human monocytes suitable for chemotaxis, cellular adhesion assays, macrophage and dendritic cell differentiation. J Immunol Methods. 2004;288:123-134.
19. Sorg RV, Ozcan Z, Brefort T, et al. Clinical-scale generation of dendritic cells in a closed system. J Immunother. 2003;26:374-383.
20. Riviere I, Brose K, Mulligan RC. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci USA. 1995;92:6733-6737.
21. Gallardo HF, Tan C, Sadelain M. The internal ribosomal entry site of the encephalomyocarditis virus enables reliable coexpression of two transgenes in human primary T lymphocytes. Gene Ther. 1997;4:1115-1119.
22. Gallardo HF, Tan C, Ory D, et al. Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes. Blood. 1997;90:952-957.
23. Richel DJ, Johnsen HE, Canon J, et al. Highly purified CD34+ cells isolated using magnetically activated cell selection provide rapid engraftment following high-dose chemotherapy in breast cancer patients. Bone Marrow Transplant. 2000;25:243-249.
24. Yuan J, Latouche JB, Hodges J, et al. Langerhans-type dendritic cells genetically modified to express full-length antigen optimally stimulate CTLs in a CD4-dependent manner. J Immunol. 2006;176:2357-2365.
25. Li C, Lai CF, Sigman DS, et al. Cloning of a cellular factor, interleukin binding factor, that binds to NFAT-like motifs in the human immunodeficiency virus long terminal repeat. Proc Natl Acad Sci USA. 1991;88:7739-7743.
26. Britten CM, Meyer RG, Kreer T, et al. The use of HLA-A*0201- transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays. J Immunol Methods. 2002;259:95-110.
27. Steinman RM, Pope M. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest. 2002;109:1519-1526.
28. Paczesny S, Banchereau J, Wittkowski KM, et al. Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells. J Exp Med. 2004;199:1503-1511.
29. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol. 2003;15:138-147.
30. Rossi M, Young JW. Human dendritic cells: potent antigenpresenting cells at the crossroads of innate and adaptive immunity. J Immunol. 2005;175:1373-1381.
31. Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitorderived dendritic cell vaccine. Cancer Res. 2001;61:6451-6458.
32. Weissman D, Ni H, Scales D, et al. HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response. J Immunol. 2000;165:4710-4717.
33. Fehse B, Kustikova OS, Bubenheim M, et al. Pois(s)on - it's a question of dose. Gene Ther. 2004;11:879-881.
34. Kustikova OS, Wahlers A, Kuhlcke K, et al. Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood. 2003;102:3934-3937.